Alpha Signal Monitor - Daily Market Briefing | March 03, 2026
Daily Market Research Report
March 03, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Gold ETFs (GLD, IAU, BAR) — Institutional Outlook Snapshot as of March 3, 2026
Trading Idea: Buy on pullbacks (core long). Rationale (TL;DR): Consensus across major houses is still bullish into 2H26 on central‑bank and investor demand plus easier policy; only Citi is notably bearish. Expect elevated volatility but higher highs into year‑end, favoring phased accumulation of physically backed gold ETFs. (jpmorgan.com)
Gold printed a series of new records into early 2026 as investors sought havens amid Middle East tensions, with banks highlighting robust central‑bank buying, rising ETF demand, and an expected drift lower in U.S. real rates as the Fed continues easing. Price action is volatile, but CIO desks still flag gold as a preferred hedge in portfolios. (ft.com)
Key Drivers - Official‑sector (central‑bank) accumulation remains structurally strong and is expected to stay elevated in 2026, tightening available float. (jpmorgan.com) - Declining or lower-for-longer U.S. real rates reduce the opportunity cost of holding gold and tend to support ETF inflows. (ubs.com) - ETF demand has re‑accelerated; even modest increases in private‑sector ownership could move price materially given under‑ownership. (morganstanley.com) - Macro and geopolitical uncertainty (U.S. policy path, Iran tensions, de‑globalization pressures) sustains a hedge bid for bullion. (ft.com)
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Bullish/Overweight | $4,900/oz by Dec 2026 (raised from $4,000 by mid‑2026 prior view). | GS cites structurally strong central‑bank buying, scope for renewed ETF inflows, and under‑ownership by U.S. investors; sees upside risk if private‑sector allocations rise. (markets.businessinsider.com) | December 11, 2025 | (markets.businessinsider.com) |
| Morgan Stanley | Positive/Bullish (Wealth Management & Research) | $4,400/oz 2026 base case; potential to ~$4,500 by mid‑2026. | MS highlights falling USD, lower real rates, strong ETF and central‑bank demand; revised 2026 forecast up to $4,400 with scope toward $4,500. (morganstanley.com) | October 31, 2025 | (investing.com) |
| JP Morgan | Bullish | Toward $5,000/oz by Q4‑2026; ~${5,055}/oz 4Q26 average; path to ~$5,400 in 2027. | JPM expects persistent official‑reserve and investor diversification into gold to push prices near $5,000 by YE26, supported by robust quarterly demand. (jpmorgan.com) | December 16, 2025 | (jpmorgan.com) |
| Bank of America | Bullish | $5,000/oz in 2026 (avg ~ $4,400). | BofA lifted its 2026 outlook to $5,000 with an average around $4,400, noting deficits, policy uncertainty and strong investment demand; flags near‑term correction risk. (investing.com) | October 13, 2025 | (investing.com) |
| Citigroup | Bearish/Underweight | $2,500–$2,700/oz by 2H‑2026 (base case); near‑term ~$3,200 (3Q25) and $3,000 (4Q25) averages referenced in interviews. | Citi argues investment demand fades as growth improves and Fed cuts progress; multiple appearances and notes guide to sub‑$3,000 with $2,500–$2,700 by 2H26. (bloomberg.com) | June 17–19, 2025 | (bloomberg.com) |
| UBS | Bullish (CIO) | $6,200/oz in the coming months; alternative house views include $5,000–$5,900 depending on scenario/timing. | UBS CIO maintains gold as a preferred hedge; Feb 20, 2026 Daily set a $6,200 near‑term target; prior CIO notes pointed to $5,000 in coming months and year‑end ~$5,900. (ubs.com) | February 20, 2026 | (ubs.com) |
| HSBC | Constructive but Cautious (volatile range) | Peak ~$5,050 in H1‑2026; year‑average ~$4,587; YE26 around ~$4,450; range ~$3,950–$5,050. | HSBC’s January 2026 note sees upside early‑year followed by possible correction later if cuts stall or risks ease; trims 2026 average but upgrades longer‑term path. (mining.com) | January 9, 2026 | (mining.com) |
| Deutsche Bank | Bullish | $4,450/oz in 2026; widened range ~$3,950–$4,950. | DB raised its 2026 forecast citing structural demand from central banks and stabilizing investor flows; notes the largest trading range since 1980 and elevated two‑way volatility. (financialexpress.com) | December 4, 2025 | (financialexpress.com) |
Risk Considerations - A hawkish Fed or stabilization in real yields could sap investment demand and trigger a deeper correction. (mining.com) - Easing geopolitical risks and stronger global growth could unwind part of the haven premium. (mining.com) - Citi’s out‑of‑consensus call sees prices falling back to $2,500–$2,700/oz by 2H26 as demand fades. (bloomberg.com) - High volatility and crowded positioning raise the risk of sharp, episodic drawdowns. (mining.com)
Position core exposure in GLD/IAU/BAR with dollar‑cost averaging and tolerance for sharp swings. Near‑term upside remains supported by policy easing and official buying, while scenario risks (hawkish Fed or geopolitics easing) argue for staggered adds and risk controls. (ubs.com)
Stock Ratings — Mega-cap tech: latest targets and ratings from GS, MS, JPM, BAC, C, WFC (as of March 3, 2026)
AAPL - Apple Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $320 | 2025-10-31 | Maintained Buy; target raised post FQ4 FY25. | https://es.investing.com/news/analyst-ratings/goldman-sachs-eleva-el-precio-objetivo-de-apple-a-320-dolares-por-fuerte-demanda-93CH-3369339 |
| Morgan Stanley | Buy | $315 | 2025-12-17 | Overweight maintained; target raised to $315. | https://appleinsider.com/articles/25/12/17/morgan-stanley-raises-apple-stock-target-to-315-citing-incredible-2026 |
| JP Morgan | Buy | $315 | 2026-01-26 | Overweight maintained; ahead of earnings. | https://macdailynews.com/2026/01/26/jpmorgan-boosts-apple-price-target-to-315-ahead-of-earnings-citing-strong-iphone-17-demand/ |
| Bank of America | Buy | $320 | 2025-10-29 | Raised from $270 on new 5-year outlook. | https://finance.yahoo.com/news/apple-stock-target-raised-bofa-135505743.html |
| Citigroup | Buy | $200 | 2025-05-21 | Buy rating and $200 PT reiterated. | https://www.investing.com/news/analyst-ratings/citi-maintains-buy-rating-and-200-target-on-alphabet-stock-4056278 |
| Wells Fargo | Buy | $290 | 2025-10-21 | Overweight; target raised to $290. | https://www.gurufocus.com/news/3152412/aapl-wells-fargo-raises-price-target-to-290-maintains-overweight-rating-aapl-stock-news |
Consensus View - Rating: Buy, Target Price: $293 - Broadly positive; targets cluster around high-$200s to low-$300s.
MSFT - Microsoft Corp.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $655 | 2026-01-12 | Buy reiterated; AI exposure cited. | https://www.barrons.com/articles/microsoft-stock-ai-strategy-goldman-c57678e4 |
| Morgan Stanley | Buy | $650 | 2026-01-14 | Overweight reiterated at $650. | https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-microsoft-stock-at-650-93CH-4446158 |
| JP Morgan | Buy | $475 | 2025-05-01 | Overweight reiterated; PT to $475. | https://www.investing.com/news/analyst-ratings/jpmorgan-raises-microsoft-stock-price-target-to-475-4015871 |
| Bank of America | Buy | $585 | 2025-07-21 | Buy; AI/Copilot momentum. | https://www.gurufocus.com/news/2990654/top-analyst-calls-microsoft-a-top-pick-hikes-target-to-585-on-azure-ai-momentum |
| Citigroup | Buy | $635 | 2026-01-29 | PT cut to $635 from $660; Buy maintained. | https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-given-new-63500-price-target-at-citigroup-2026-01-29/ |
| Wells Fargo | Buy | $630 | 2026-01-22 | Overweight; target trimmed from $665 to $630. | https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-lowered-to-63000-at-wells-fargo-company-2026-01-22/ |
Consensus View - Rating: Buy, Target Price: $605 - Consensus remains Buy with AI tailwinds; targets centered around ~$600.
GOOGL - Alphabet Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $400 | 2026-02-05 | PT raised to $400 post Q4 FY2025. | https://m.ca.investing.com/news/analyst-ratings/goldman-sachs-raises-alphabet-stock-price-target-to-400-on-strong-cloud-growth-93CH-4439789?ampMode=1 |
| Morgan Stanley | Buy | $330 | 2025-10-30 | Overweight; PT raised to $330. | https://www.gurufocus.com/news/3172847/googl-morgan-stanley-raises-price-target-amid-overweight-rating-googl-stock-news |
| JP Morgan | Buy | $385 | 2025-12 | Overweight; PT to $385. | https://www.tipranks.com/news/the-fly/alphabet-price-target-raised-to-385-from-340-at-jpmorgan-thefly |
| Bank of America | Buy | $280 | 2025-10-20 | Buy; ahead of Oct 29 earnings. | https://www.investing.com/news/analyst-ratings/bofa-securities-raises-alphabet-stock-price-target-to-280-on-ad-strength-93CH-4296307 |
| Citigroup | Buy | $200 | 2025-04-25 | Buy and $200 PT maintained/raised in spring 2025 updates. | https://www.investing.com/news/analyst-ratings/citi-raises-alphabet-stock-price-target-to-200-maintains-buy-rating-4004059 |
| Wells Fargo | Buy | $387 | 2026-02-23 | Upgraded to Overweight; PT to $387. | https://m.in.investing.com/news/analyst-ratings/wells-fargo-upgrades-alphabet-stock-rating-on-compute-capacity-expansion-93CH-5251063?ampMode=1 |
Consensus View - Rating: Buy, Target Price: $330 - Strong Buy skew; multiple recent PT hikes after solid Cloud/Search.
AMZN - Amazon.com Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $275 | 2025-10-03 | Buy maintained; PT raised on AWS outlook. | https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-amazon-stock-price-target-to-275-on-aws-growth-outlook-93CH-4270016 |
| Morgan Stanley | Buy | $300 | 2025-07-11 | Top pick; PT raised to $300. | https://www.investing.com/news/stock-market-news/bofa-sees-35-upside-in-amazon-stock-after-price-target-update-4132024 |
| JP Morgan | Buy | $255 | 2025-07-11 | Overweight; PT to $255. | https://www.gurufocus.com/news/2971607/jpmorgan-increases-price-target-for-amazon-amzn-to-255-amzn-stock-news |
| Bank of America | Buy | $303 | 2025-12-03 | Buy; BofA stays bullish into 2026. | https://www.tipranks.com/news/bank-of-america-stays-bullish-on-amazon-stock-amzn-says-aws-ai-sentiment-key-driver-in-2026 |
| Citigroup | Buy | $265 | 2025-07-22 | PT raised to $265; Buy maintained. | https://it.investing.com/news/analyst-ratings/citi-alza-il-target-di-prezzo-del-titolo-amazon-a-265-grazie-alle-prospettive-di-crescita-di-aws-93CH-2912290 |
| Wells Fargo | Buy | $280 | 2025-09-24 | Upgraded to Overweight; PT to $280. | https://www.nasdaq.com/articles/wells-fargo-upgrades-amazoncom-amzn |
Consensus View - Rating: Buy, Target Price: $280 - Consensus Buy with targets clustered around $275–$300; AWS acceleration is the key driver.
NVDA - NVIDIA Corp.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $250 | 2026-02-25 | Buy reiterated; PT maintained post results. | https://www.investing.com/news/analyst-ratings/nvidia-stock-price-target-maintained-at-250-by-goldman-sachs-93CH-4526094 |
| Morgan Stanley | Buy | $260 | 2026-03-02 | Overweight reiterated at $260. | https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-nvidia-stock-at-260-93CH-4533721 |
| JP Morgan | Buy | $265 | 2026-02-26 | Buy maintained; PT lifted to $265. | https://investinglive.com/stocks/nvidia-gets-fresh-wall-street-backing-jpmorgan-lifts-target-to-265-ubs-flags-ai-upside-20260226// |
| Bank of America | Buy | $275 | 2026-01-06 | Buy reiterated at $275 following CES 2026. | https://www.investing.com/news/analyst-ratings/bofa-securities-reaffirms-nvidia-stock-buy-rating-with-275-price-target-93CH-4431532 |
| Citigroup | Buy | $270 | 2026-02-17 | Buy maintained; H2’26 outperformance expected. | https://www.investing.com/news/stock-market-news/citi-says-buy-nvidia-stock-ahead--2h26-outperformance-4508233 |
| Wells Fargo | Buy | $265 | 2025-11-14 | Overweight; PT raised to $265. | https://www.gurufocus.com/news/3209758/wells-fargo-raises-nvidia-nvda-price-target-to-265-nvda-stock-news |
Consensus View - Rating: Buy, Target Price: $264 - All six positive; AI demand supports multi-year outlook.
META - Meta Platforms Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $690 | 2025-05-01 | Buy; PT lifted to $690. | https://id.investing.com/news/analyst-ratings/goldman-sachs-naikkan-target-harga-meta-platforms-ke-690-93CH-2774445 |
| Morgan Stanley | Buy | $750 | 2026-01 | Overweight; PT reduced to $750 in early 2026 on capex debate. | https://www.marketwatch.com/story/metas-stock-may-actually-be-an-overlooked-ai-winner-why-bulls-say-to-buy-the-dip-918adf90 |
| JP Morgan | Buy | $735 | 2025-06-04 | Overweight; PT raised to $735. | https://id.investing.com/news/analyst-ratings/jpmorgan-naikkan-target-harga-saham-meta-berdasarkan-potensi-pertumbuhan-93CH-2802527 |
| Bank of America | Buy | $690 | 2025-05-01 | Buy; PT raised post Q1 beat. | https://www.tipranks.com/news/the-fly/meta-platforms-price-target-raised-to-690-from-640-at-bofa |
| Citigroup | Buy | $915 | 2025-09-18 | Buy; raised after Connect event. | https://in.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-meta-stock-maintains-915-price-target-93CH-5009870 |
| Wells Fargo | Buy | $856 | 2026-02-23 | Overweight; PT nudged to $856. | https://www.gurufocus.com/news/8643693/wells-fargo-raises-price-target-for-meta-stock-to-856-meta-stock-news |
Consensus View - Rating: Buy, Target Price: $773 - Consensus very bullish; targets concentrated in $690–$900 range.
TSLA - Tesla Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Hold | $395 | 2025-09-18 | Neutral maintained; PT raised to $395. | https://price-target.com/2025/09/18/163619/ |
| Morgan Stanley | Hold | $425 | 2026-01-02 | Equal-weight; robotaxi seen as key 1H26 catalyst. | https://www.investing.com/news/analyst-ratings/morgan-stanley-maintains-tesla-stock-rating-citing-robotaxi-catalyst-93CH-4428086 |
| JP Morgan | Sell | $150 | 2025-10-03 | Underweight; PT raised to $150 from $115. | https://price-target.com/2025/10/03/163772/ |
| Bank of America | - | - | - | - | - |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Rating: Hold, Target Price: $323 - Mixed views (Neutral/Equal-weight vs. Underweight); limited data from some institutions.
AVGO - Broadcom Inc.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $435 | 2025-11-26 | Buy; target raised on accelerating AI custom silicon. | https://www.gurufocus.com/news/3225513/goldman-sachs-raises-price-target-on-broadcom-avgo-to-435-reaffirms-buy-rating-avgo-stock-news |
| Morgan Stanley | - | - | - | - | - |
| JP Morgan | - | - | - | - | - |
| Bank of America | Buy | $500 | 2025-12-12 | Buy; PT raised on AI growth. | https://www.investing.com/news/analyst-ratings/broadcom-stock-price-target-raised-to-500-by-bofa-on-ai-growth-93CH-4405225 |
| Citigroup | - | - | - | - | - |
| Wells Fargo | Buy | $430 | 2026-01-15 | Upgraded to Overweight; PT to $430. | https://www.investing.com/news/analyst-ratings/wells-fargo-upgrades-broadcom-stock-rating-on-ai-growth-potential-93CH-4449457 |
Consensus View - Rating: Buy, Target Price: $455 - Limited data but all covered banks are positive; average of available PTs ~ $455.
TSM - Taiwan Semiconductor Manufacturing Co. (ADR)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | NT$2,600 | 2026-01-16 | Conviction Buy; Street‑high local-currency PT. | https://vn.investing.com/news/analyst-ratings/goldman-sachs-nang-muc-tieu-gia-tsmc-len-nt2600-nho-tang-truong-ai-93CH-2513168 |
| Morgan Stanley | Buy | NT$1,888 | 2025-12-18 | Overweight; recommends adding before 2026. | https://www.investing.com/news/stock-market-news/morgan-stanley-recommends-adding-to-this-major-chip-stock-ahead-of-2026-4414968 |
| JP Morgan | Buy | NT$2,100 | 2026-01-07 | Overweight; AI-led multi‑year growth. | https://www.investing.com/news/analyst-ratings/jpmorgan-raises-tsmc-stock-price-target-to-nt2100-on-ai-growth-outlook-93CH-4434161 |
| Bank of America | Buy | NT$1,600 | 2025-10-07 | Buy; improved pricing outlook and 2026 ramp. | https://www.investing.com/news/stock-market-news/bofa-raises-tsmc-target-sees-improved-pricing-outlook-4275321 |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Rating: Buy, Target Price: NT$2,047 - Average of available local-currency targets from GS/MS/JPM/BAC indicates strong Buy skew.
IPO Calendar
Timeframe: March 3, 2026 to April 2, 2026 (U.S. equity markets)
The near-term U.S. IPO calendar is led by Medtronic’s carve-out of its Diabetes business, MiniMed (MMED), which has launched a roadshow to list on Nasdaq with a $25–$28 range and 28.0 million shares; pricing is guided for Thursday, March 5, 2026, with first trade typically the following day. Biotech issuance remains active but selective: Generate Biomedicines (GENB) priced $400 million on February 26 and traded down in early sessions, while Salspera (TKVA) has set terms ($14–$16; 5.7 million shares) but has not posted a firm date and could price on short notice in early March. Overall activity is still sensitive to volatility—underscored by Clear Street’s day‑of‑listing postponement in mid‑February—so calendars can change quickly; February’s usual lull tied to year‑end audits is easing into a March window that may open for additional issuers if markets stabilize. (renaissancecapital.com)
MiniMed Group, Inc. (MMED)
- Expected listing date: March 5, 2026 (pricing; first trade expected March 6, 2026)
- Price range: $25.00 – $28.00 per share
- Shares offered: 28,000,000 primary shares; 30‑day option for 4,200,000 additional shares
- Exchange: Nasdaq Global Select Market
- Lead underwriters: Goldman Sachs & Co. LLC, BofA Securities, Citigroup, Morgan Stanley, Barclays, Deutsche Bank, Mizuho Securities, Wells Fargo Securities, Evercore ISI, Piper Sandler, BTIG, William Blair
- Business summary: Carve‑out of Medtronic’s Diabetes business, a scaled global medical technology company focused on integrated diabetes management (insulin delivery pumps, continuous glucose monitors, smart insulin pens, and related software/services). Large installed base (>640k pump users as of Oct‑2025) with a high recurring‑revenue mix from CGMs, consumables, software and services.
- Notes: Roadshow launched February 24, 2026; pricing guided for March 5, 2026 and listing on Nasdaq under MMED thereafter. Medtronic is expected to retain ~90% voting power post‑IPO; terms, timing, and size remain subject to market conditions and SEC effectiveness.
- Sources: https://www.renaissancecapital.com/IPO-Center/News/117345/US-IPO-Week-Ahead-Medtronic-carve-out-MiniMed-to-kick-off-March-calendar, https://www.renaissancecapital.com/Profile/MMED/MiniMed/IPO, https://news.medtronic.com/2026-02-24-MiniMed-announces-launch-of-IPO-roadshow, https://finance.yahoo.com/news/medtronic-diabetes-unit-minimed-seeks-170246797.html, https://www.sec.gov/Archives/edgar/data/0002062583/000162828026012865/minimedgroupincs-1a3.htm
Salspera, Inc. (TKVA)
- Expected listing date: March 2026 (timing TBC)
- Price range: $14.00 – $16.00 per share
- Shares offered: 5,700,000 shares (base deal)
- Exchange: Nasdaq (proposed)
- Lead underwriters: Kingswood Capital Markets
- Business summary: Clinical‑stage immuno‑oncology company developing “live biopharmaceuticals” (engineered bacteria) designed to express IL‑2 in the tumor microenvironment. Lead program, Saltikva, targets metastatic pancreatic cancer, with plans for pivotal studies; additional programs in other solid tumors.
- Notes: Company set terms on February 23, 2026; no firm pricing/trading date disclosed as of March 3, 2026. Offering size/timing may change or be withdrawn depending on market conditions.
- Sources: https://www.renaissancecapital.com/Profile/TKVA/Salspera/IPO, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO, https://www.sec.gov/Archives/edgar/data/2084032/000121390026010732/0001213900-26-010732-index.htm
The Metals Royalty Company (TMCR)
- Expected listing date: March 2026 (direct listing; timing TBC)
- Price range: $5.00 (reference price in filing)
- Shares offered: 55.1 million shares registered for direct listing (no primary proceeds)
- Exchange: Nasdaq (proposed)
- Lead underwriters: Stifel (financial advisor)
- Business summary: Canadian critical‑metals and minerals royalty/streaming company. Core asset is a 2.0% gross overriding royalty on the NORI polymetallic nodule project in the Clarion‑Clipperton Zone of the Pacific Ocean; strategy focuses on financing exposure to strategic metals with reduced operating risk.
- Notes: Planned U.S. direct listing rather than a traditional underwritten IPO; deal size shown as $0 given no primary proceeds. Inclusion here reflects a new U.S. listing expected in the coming month; timing subject to SEC effectiveness and market conditions.
- Sources: https://www.renaissancecapital.com/Profile/TMCR/The-Metals-Royalty-Co/IPO, https://www.renaissancecapital.com/IPO-Center/Calendar
Motive Technologies, Inc. (MTVE)
- Exchange: NYSE (proposed)
- Lead underwriters: J.P. Morgan, Citigroup, Barclays, Jefferies, RBC Capital Markets, Citizens JMP, KeyBanc Capital Markets, Société Générale (SG Americas), Nomura (Wolfe | Nomura Alliance)
- Business summary: AI‑enabled fleet and physical‑operations platform (telematics hardware, AI dashcams, safety, spend/workforce management) serving logistics, construction, energy, manufacturing and public‑sector customers; filed to go public and could set terms as markets stabilize.
- Notes: Filed an S‑1 on December 23, 2025; no price range, share count, or date disclosed as of March 3, 2026. Renaissance Capital notes Motive as eligible to launch roadshow; inclusion as an expected prospect for the March window is tentative.
- Sources: https://www.renaissancecapital.com/IPO-Center/News/115794/Fleet-management-software-provider-Motive-Technologies-files-for-a-%24100-mil, https://www.renaissancecapital.com/Profile/MTVE/Motive-Technologies/IPO
Grayscale Investments, Inc. (GRAY)
- Exchange: NYSE (proposed)
- Lead underwriters: Morgan Stanley, BofA Securities, Jefferies, Cantor Fitzgerald, Wells Fargo Securities, Canaccord Genuity, Piper Sandler, Keefe, Bruyette & Woods, Needham & Company, The Benchmark Company, Compass Point
- Business summary: Crypto‑asset manager offering a broad suite of digital‑asset investment products (including spot/mini-trust ETPs) with ~$35 billion AUM as of September 30, 2025; pursuing a corporate IPO to list on NYSE under GRAY.
- Notes: Public S‑1 filed November 13, 2025; no terms or date disclosed as of March 3, 2026. Inclusion reflects a potential to move in March if conditions permit; timing remains uncertain.
- Sources: https://www.renaissancecapital.com/Profile/GRAY/Grayscale-Investments/IPO, https://www.renaissancecapital.com/IPO-Center/News/114931/Crypto-investment-platform-Grayscale-Investments-files-for-a-%24100-million-I, https://www.globenewswire.com/news-release/2025/11/13/3187426/0/en/Grayscale-Investments-Announces-Public-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html
IPO calendars are fluid. Dates, ranges, share counts, exchanges, and syndicate rosters can change—or deals may be postponed or withdrawn—based on market conditions and SEC review. This calendar reflects information verified as of March 3, 2026 from primary filings and reputable IPO trackers; monitor issuer and exchange announcements for updates. Key context on volatility: Clear Street’s February 13 postponement highlighted window fragility; February’s typical lull tied to year‑end audits is now transitioning into March, when additional issuers may post terms quickly. (ft.com)
Sources
- Stock Ratings: https://appleinsider.com/articles/25/12/17/morgan-stanley-raises-apple-stock-target-to-315-citing-incredible-2026, https://es.investing.com/news/analyst-ratings/goldman-sachs-eleva-el-precio-objetivo-de-apple-a-320-dolares-por-fuerte-demanda-93CH-3369339, https://finance.yahoo.com/news/apple-stock-target-raised-bofa-135505743.html, https://id.investing.com/news/analyst-ratings/goldman-sachs-naikkan-target-harga-meta-platforms-ke-690-93CH-2774445, https://id.investing.com/news/analyst-ratings/jpmorgan-naikkan-target-harga-saham-meta-berdasarkan-potensi-pertumbuhan-93CH-2802527, https://in.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-meta-stock-maintains-915-price-target-93CH-5009870, https://investinglive.com/stocks/nvidia-gets-fresh-wall-street-backing-jpmorgan-lifts-target-to-265-ubs-flags-ai-upside-20260226//, https://it.investing.com/news/analyst-ratings/citi-alza-il-target-di-prezzo-del-titolo-amazon-a-265-grazie-alle-prospettive-di-crescita-di-aws-93CH-2912290, https://m.ca.investing.com/news/analyst-ratings/goldman-sachs-raises-alphabet-stock-price-target-to-400-on-strong-cloud-growth-93CH-4439789?ampMode=1, https://m.in.investing.com/news/analyst-ratings/wells-fargo-upgrades-alphabet-stock-rating-on-compute-capacity-expansion-93CH-5251063?ampMode=1, https://macdailynews.com/2026/01/26/jpmorgan-boosts-apple-price-target-to-315-ahead-of-earnings-citing-strong-iphone-17-demand/, https://price-target.com/2025/09/18/163619/, https://price-target.com/2025/10/03/163772/, https://vn.investing.com/news/analyst-ratings/goldman-sachs-nang-muc-tieu-gia-tsmc-len-nt2600-nho-tang-truong-ai-93CH-2513168, https://www.barrons.com/articles/microsoft-stock-ai-strategy-goldman-c57678e4, https://www.gurufocus.com/news/2971607/jpmorgan-increases-price-target-for-amazon-amzn-to-255-amzn-stock-news, https://www.gurufocus.com/news/2990654/top-analyst-calls-microsoft-a-top-pick-hikes-target-to-585-on-azure-ai-momentum, https://www.gurufocus.com/news/3152412/aapl-wells-fargo-raises-price-target-to-290-maintains-overweight-rating-aapl-stock-news, https://www.gurufocus.com/news/3172847/googl-morgan-stanley-raises-price-target-amid-overweight-rating-googl-stock-news, https://www.gurufocus.com/news/3209758/wells-fargo-raises-nvidia-nvda-price-target-to-265-nvda-stock-news, https://www.gurufocus.com/news/3225513/goldman-sachs-raises-price-target-on-broadcom-avgo-to-435-reaffirms-buy-rating-avgo-stock-news, https://www.gurufocus.com/news/8643693/wells-fargo-raises-price-target-for-meta-stock-to-856-meta-stock-news, https://www.investing.com/news/analyst-ratings/bofa-securities-raises-alphabet-stock-price-target-to-280-on-ad-strength-93CH-4296307, https://www.investing.com/news/analyst-ratings/bofa-securities-reaffirms-nvidia-stock-buy-rating-with-275-price-target-93CH-4431532, https://www.investing.com/news/analyst-ratings/broadcom-stock-price-target-raised-to-500-by-bofa-on-ai-growth-93CH-4405225, https://www.investing.com/news/analyst-ratings/citi-maintains-buy-rating-and-200-target-on-alphabet-stock-4056278, https://www.investing.com/news/analyst-ratings/citi-raises-alphabet-stock-price-target-to-200-maintains-buy-rating-4004059, https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-amazon-stock-price-target-to-275-on-aws-growth-outlook-93CH-4270016, https://www.investing.com/news/analyst-ratings/jpmorgan-raises-microsoft-stock-price-target-to-475-4015871, https://www.investing.com/news/analyst-ratings/jpmorgan-raises-tsmc-stock-price-target-to-nt2100-on-ai-growth-outlook-93CH-4434161, https://www.investing.com/news/analyst-ratings/morgan-stanley-maintains-tesla-stock-rating-citing-robotaxi-catalyst-93CH-4428086, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-microsoft-stock-at-650-93CH-4446158, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-nvidia-stock-at-260-93CH-4533721, https://www.investing.com/news/analyst-ratings/nvidia-stock-price-target-maintained-at-250-by-goldman-sachs-93CH-4526094, https://www.investing.com/news/analyst-ratings/wells-fargo-upgrades-broadcom-stock-rating-on-ai-growth-potential-93CH-4449457, https://www.investing.com/news/stock-market-news/bofa-raises-tsmc-target-sees-improved-pricing-outlook-4275321, https://www.investing.com/news/stock-market-news/bofa-sees-35-upside-in-amazon-stock-after-price-target-update-4132024, https://www.investing.com/news/stock-market-news/citi-says-buy-nvidia-stock-ahead--2h26-outperformance-4508233, https://www.investing.com/news/stock-market-news/morgan-stanley-recommends-adding-to-this-major-chip-stock-ahead-of-2026-4414968, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-given-new-63500-price-target-at-citigroup-2026-01-29/, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-lowered-to-63000-at-wells-fargo-company-2026-01-22/, https://www.marketwatch.com/story/metas-stock-may-actually-be-an-overlooked-ai-winner-why-bulls-say-to-buy-the-dip-918adf90, https://www.nasdaq.com/articles/wells-fargo-upgrades-amazoncom-amzn, https://www.tipranks.com/news/bank-of-america-stays-bullish-on-amazon-stock-amzn-says-aws-ai-sentiment-key-driver-in-2026, https://www.tipranks.com/news/the-fly/alphabet-price-target-raised-to-385-from-340-at-jpmorgan-thefly, https://www.tipranks.com/news/the-fly/meta-platforms-price-target-raised-to-690-from-640-at-bofa
- IPO Calendar: https://finance.yahoo.com/news/medtronic-diabetes-unit-minimed-seeks-170246797.html, https://news.medtronic.com/2026-02-24-MiniMed-announces-launch-of-IPO-roadshow, https://www.ft.com/content/e0c71b94-b761-496c-a251-f106cbb9353a?utm_source=openai, https://www.globenewswire.com/news-release/2025/11/13/3187426/0/en/Grayscale-Investments-Announces-Public-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html, https://www.renaissancecapital.com/IPO-Center/Calendar, https://www.renaissancecapital.com/IPO-Center/News/114931/Crypto-investment-platform-Grayscale-Investments-files-for-a-%24100-million-I, https://www.renaissancecapital.com/IPO-Center/News/115794/Fleet-management-software-provider-Motive-Technologies-files-for-a-%24100-mil, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO, https://www.renaissancecapital.com/IPO-Center/News/117345/US-IPO-Week-Ahead-Medtronic-carve-out-MiniMed-to-kick-off-March-calendar, https://www.renaissancecapital.com/Profile/GRAY/Grayscale-Investments/IPO, https://www.renaissancecapital.com/Profile/MMED/MiniMed/IPO, https://www.renaissancecapital.com/Profile/MTVE/Motive-Technologies/IPO, https://www.renaissancecapital.com/Profile/TKVA/Salspera/IPO, https://www.renaissancecapital.com/Profile/TMCR/The-Metals-Royalty-Co/IPO, https://www.sec.gov/Archives/edgar/data/0002062583/000162828026012865/minimedgroupincs-1a3.htm, https://www.sec.gov/Archives/edgar/data/2084032/000121390026010732/0001213900-26-010732-index.htm
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-03-03 at 11:23 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI
Don't miss what's next. Subscribe to Alpha: